Qing Yi, MD PhD
Houston Methodist Research Institute
I am a translational tumor immunologist. I have 30 years of experience as a well-funded and published researcher and am one of the leading investigators in the fields of tumor immunology in myeloma and other cancers. My laboratory has been working on: (1) characterizing myeloma- and tumor-specific T cells and their subsets and examining their functions, (2) identifying novel myeloma-associated antigens and better methods for immunotherapy, (3) investigating the cross-talk between the tumor microenvironment (TME) and immune system, (4) conducting clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines, and (5) exploring immunotherapies using myeloma antigens such as DKK1. Our recent research focuses on: (a) developing novel therapeutic mAbs and CAR-T cells for cancers, (b) identifying T-cell subsets that have potent antitumor effects after adoptive transfer, and (c) identifying TME components that induce tumor drug resistance.